Lung Cancer Screening: The Cost of Inaction
The Lung Ambition Alliance is proud to release a new report that highlights the potential of lung cancer screening to improve patient outcomes while also reducing the cost burden on healthcare systems.
Targeted screening could reduce costs and save lives
Lung Cancer Screening: The Cost of Inaction, developed for the Lung Ambition Alliance by The Health Policy Partnership, is a comprehensive review of the clinical and cost effectiveness evidence for lung cancer screening in targeted populations using low-dose CT scans. It is designed to further understanding of the key issues surrounding screening, why it is needed, and how earlier diagnosis of lung cancer presents a crucial opportunity to reduce costs while saving lives.
We encourage anyone with an interest in public health policy and improving care for people with lung cancer to read the report and share its recommendations.
The report has been endorsed by both the Lung Ambition Alliance and the International Association for the Study of Lung Cancer. It was initiated and funded by AstraZeneca, a founding partner of the Lung Ambition Alliance.